Equillium
EQ
Equillium (EQ) news
Recent news
Equillium - Topline phase 1 data expected six months after study initiation
AInvest Wire · Oct 5, 2026Equillium - Expects to begin dosing by early November 2026
Equillium, Inc. (NASDAQ: EQ) is anticipated to begin dosing patients in its clinical trials by early November 2026, according to recent developments. This timeline aligns with the company’s ongoing efforts to advance its pipeline of investigational therapies, particularly in the areas of oncology…
AInvest Wire · Oct 5, 2026Equillium receives Australian regulatory clearance to initiate first-in-human clinical trial of EQ504
AInvest Wire · Oct 5, 2026Equillium Q2 operating income USD -5.155 million vs. IBES estimate USD -6.14 million
AInvest Wire · Aug 13, 2026Equillium Q2 operating expenses USD 5.155 million
AInvest Wire · Aug 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.